Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 28Neoplasm Metastasis 9Neoplasms 8Brain Neoplasms 5Triple Negative Breast Neoplasms 3Recurrence 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3Glioma 3Endometrial Neoplasms 3Breast Diseases 3Squamous Cell Carcinoma of Head and Neck 2Meningioma 2Liposarcoma 2Head and Neck Neoplasms 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neurofibromatosis 1 1Neoplasms, Squamous Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1

Interventions

Specimen Handling 3Doxorubicin 3Biopsy 3Radiotherapy 2Radiation 2Magnetic Resonance Spectroscopy 2Gemcitabine 2toripalimab 1talimogene laherparepvec 1ribociclib 1peposertib 1pazopanib 1liposomal doxorubicin 1cabozantinib 1abemaciclib 1Temozolomide 1Surgical Procedures, Operative 1PM 01183 1Nivolumab 1Neoadjuvant Therapy 1Ifosfamide 1Everolimus 1Docetaxel 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leiomyosarcoma × abemaciclib × 90 days × Clear all
NCT06498648 2026-05-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
74 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡